LB Pharmaceuticals announces a $100 million private placement of common stock and pre-funded warrants with institutional investors to fund a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.
https://finviz.com/quote.ashx?t=LBRX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.